Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8028711 | 0.79 | MAPK1 (0.43) | MAPK1 | |
| SCHEMBL13652189 | 0.78 | MAPK1 (0.32) | MAPK1 | |
| SCHEMBL14182577 | 0.74 | MAPK1 (0.41) | MAPK1 | |
| SCHEMBL1801477 | 0.73 | — | — | |
| SCHEMBL23096048 | 0.71 | MAPK1 (0.32) | MAPK1 | |
| SCHEMBL1739227 | 0.71 | MAPK1 (0.37) | MAPK1 | |
| SCHEMBL40975 | 0.71 | LMNA (0.35) | MEN1HTTKMT2ANPSR1 | |
| SCHEMBL13509577 | 0.70 | TSHR (0.46) | MAPK1MEN1KMT2A | |
| SCHEMBL841703 | 0.69 | XPO1 (0.32) | — | |
| SCHEMBL3296405 | 0.68 | LMNA (0.33) | MEN1HTTKMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7655804-B2 | N-[(1S)-3-{(2Z)-2-[(4R)-3,4-dimethyl-1,3-thiazolidin-2-ylidene]hydrazino}-2,3-dioxo-1-(tetrahydro-2H-pyran-4-yl)propyl]cycloheptanecarboxamide; cysteine protease inhibitors; for the treatment of inflammatory, immune, ischemic, respiratory,circulatory, neuronal, blood, hepatic and metabolic diseases | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-02-02 | — | — | US | disclosed |
| US-20060111303-A1 | Diketohydrazine derivative compounds and drugs contaiing the compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111303-A1 | Diketohydrazine derivative compounds and drugs contaiing the compounds as the active ingredient | SERPINB1, CTSZ, SERPINE1 | MAPK1 1173/4885MEN1 2998/4885HTT 1349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.